ClinicalTrials.gg
CompletedNCT02084199Updated Jul 22, 2014

Study to Evaluate GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects

A Phase 1 interventional study of GLPG0634 in Renal Impairment, sponsored by Galapagos NV. Completed at 1 site in Germany. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-22.

Sponsored by Galapagos NV · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 139 studies in Renal Insufficiency with a site in Germany — 12 open to participants now, 16 under way, 2 of them phase 3. Renal Insufficiency · Germany.

Enrollment
94th of 113
24 · median 42
Started
2014
with 6 others
Phase 1
54 of 139
1 open now
Registered
56th of 139
by date

Among the 139 studies in Renal Insufficiency with a site in Germany, this one is the 94th largest by enrollment of the 113 interventional ones that give a count, is one of 7 that started in 2014, is one of 54 in phase 1, and was the 56th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

12 of the 139 studies in Renal Insufficiency with a site in Germany are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Renal Insufficiency with a site in Germany, or all of them as a file.
02

Study summary

This will be an open label study to assess the influence of renal impairment on the pharmacokinetics (PK) of GLPG0634 and its metabolite after once daily oral administrations of 100 mg GLPG0634 for 10 days in subjects with renal impairment and matched healthy controls.

Also, safety and tolerability of once daily oral doses of GLPG0634 for 10 days in subjects with renal impairment and matched healthy controls will be evaluated.

Read the detailed description

The study will be divided in two parts.

In Part 1, 3 subjects with severe renal impairment or end-stage renal disease (ESRD) not yet requiring dialysis (Group 1) will be recruited first. Thereafter, 3 subjects with normal renal function (Group 2) will be recruited. If a substantial effect on the PK in renal impaired subjects is observed on Day 10, the sponsor may elect to stop Part 1 of the study without enrolling the complete set of subjects and Part 2 will be initiated. In case no substantial effect on the PK is observed, 3 further subjects in both Group 1 and 2 will be recruited and analysed. If a substantial effect on the PK is observed, the study will proceed to Part 2. Part 2 of the study will not be conducted, if in Part 1 no substantial difference in PK is seen.

In Part 2, Group 3 (mild renal impairment) and Group 4 (moderate renal impairment) will be recruited first. After completion of the mild and moderate impairment groups, Group 5 (normal renal function) will be recruited.

03

Conditions studied

  • Renal Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female white subjects between 18-79 years of age (inclusive)
  • Subjects must have a between 18-34 kg/m², inclusive
  • Part 1, Group 1: subject with severe renal impairment or ESRD, not on dialysis : between 15-29 mL/min/1.73 m2 or \<15 mL/min/1.73m²
  • Part 1, Group 2: subject with normal renal function: eGFR ≥90 mL/min/1.73m²
  • Part 2, Group 3: subject with mild renal impairment: eGFR between 60-89 mL/min/1.73 m²
  • Part 2, Group 4:subject with moderate renal impairment: eGFR between 30-59 mL/min/1.73 m²
  • Part 2, Group 5: subject with normal renal function: eGFR ≥90 mL/min/1.73 m²
  • Subjects must be judged to be in good health (subjects with normal renal function)/in a stable condition and acceptable for study participation (subjects with renal impairment) based upon the results of a medical history, physical examination, vital signs, 12-lead , and laboratory profile

Exclusion criteria

Exclusion Criteria:

  • A subject with a known to ingredients of the study medication or a significant allergic reaction to any drug
  • Subject has previously participated in a GLPG0634 study or has previously received GLPG0634
  • Concurrent participation or participation within 8 weeks prior to the initial study drug administration in a drug/device or biologic research study
  • A subject with active drug or alcohol abuse within 2 years prior to the initial study drug administration
  • A subject who has a current child wish
  • Female subject less than 6 months post-partum, post-abortion or post-lactation prior to study drug administration or is pregnant or breastfeeding
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Part 1 - Severe renal impairment

    Part 1 - Group 1: subjects with severe renal impairment or end-stage renal disease (ESRD), not on dialysis: Estimated glomerular filtration rate (eGFR) between 15-29 mL/min/1.73 m2 or \<15 mL/min/1.73m² will be administered GLPG0634 100 mg once daily for 10 days

    Drug: GLPG0634

  • Experimental
    Part 1: Normal renal function

    Part 1 - Group 2: subjects with normal renal function: eGFR ≥90 mL/min/1.73m² will be administered GLPG0634 100 mg once daily for 10 days

    Drug: GLPG0634

  • Experimental
    Part 2 - Mild renal impairment

    Part 2 - Group 3: subjects with mild renal impairment: eGFR between 60-89 mL/min/1.73 m² will be administered GLPG0634 100 mg once daily for 10 days

    Drug: GLPG0634

  • Experimental
    Part 2 - Moderate renal impairment

    Part 2 - Group 4:subjects with moderate renal impairment: eGFR between 30-59 mL/min/1.73 m² will be administered GLPG0634 100 mg once daily for 10 days

    Drug: GLPG0634

  • Experimental
    Part 2 - Normal renal function

    Part 2 - Group 5: subjects with normal renal function: eGFR ≥90 mL/min/1.73 m² will be administered GLPG0634 100 mg once daily for 10 days

    Drug: GLPG0634

Interventions

  • 100 mg oral tablet, intake once daily for 10 days

    Also known as: GLPG0634 tablets

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Cmax of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function

    Time frame: Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)

  2. Area under the plasma drug concentration-time curve over 24 hours (AUC0-24h)

    AUC0-24h of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function

    Time frame: Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)

Secondary outcomes

  1. Cumulative amount excreted in urine expressed in μg and % of the dose administered (Ae)

    Ae of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function

    Time frame: Between dosing on Day 1 up to 48 h after dosing on Day 10 (Day 12)

  2. Renal clearance (CLR)

    CLR (calculated as Ae/AUC, where Ae and AUC are calculated over the same interval) of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function

    Time frame: Between dosing on Day 1 up to 48 h after dosing on Day 10 (Day 12)

  3. Plasma concentration observed at 24 h post-dose (C24h)

    C24h of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function

    Time frame: Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)

  4. Average plasma concentration (Cavg)

    Cavg (calculated as AUC0-24h/24h) of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function

    Time frame: Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)

  5. Time of occurrence of Cmax (tmax)

    Tmax of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function

    Time frame: Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)

  6. Area under the plasma drug concentration-time curve from zero to the last sampling time at which concentrations were at or above the limit of quantification (AUC0-z)

    AUC0-z of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function

    Time frame: Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)

  7. Area under the plasma drug concentration-time curve, extrapolated to infinity (AUC0-∞)

    AUC0-∞ of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function

    Time frame: Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)

  8. Apparent terminal half-life (t1/2,λz)

    t1/2,λz (calculated from (ln 2)/λz being the apparent terminal rate constant) of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function

    Time frame: Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)

  9. Metabolite over parent ratio of AUC0-24h (R)

    R (metabolite over parent ratio of AUC0-24h) after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function

    Time frame: Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)

  10. Accumulation ratio (Rac)

    Rac (calculated as AUC0-24h Day 10/AUC0-24h Day 1) after dosing in subjects with renal impairment versus subjects with normal renal function

    Time frame: Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)

  11. The number of subjects with adverse events

    To evaluate the safety and tolerability of GLPG0634 in subjects with renal impairment versus subjects with normal renal function in terms of adverse events (AEs)

    Time frame: From screening up to 10 days after last dose (Day 20)

  12. The number of subjects with abnormal laboratory parameters

    To evaluate the safety and tolerability of GLPG0634 in subjects with renal impairment versus subjects with normal renal function in terms of abnormal laboratory parameters

    Time frame: From screening up to 10 days after last dose (Day 20)

  13. The number of subjects with abnormal vital signs

    To evaluate the safety and tolerability of GLPG0634 in subjects with renal impairment versus subjects with normal renal function in terms of abnormal vital signs

    Time frame: From screening up to 10 days after last dose (Day 20)

  14. The number of subjects with abnormal electrocardiogram (ECG)

    To evaluate the safety and tolerability of GLPG0634 in subjects with renal impairment versus subjects with normal renal function in terms of abnormal electrocardiogram (ECG)

    Time frame: From screening up to 10 days after last dose (Day 20)

  15. The number of subjects with abnormal physical examination

    To evaluate the safety and tolerability of GLPG0634 in subjects with renal impairment versus subjects with normal renal function in terms of abnormal physical examination

    Time frame: From screening up to 10 days after last dose (Day 20)

07

Study locations

1 site
  • CRS Clinical Research Services Kiel GmbH
    Kiel, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2014
First posted
Mar 11, 2014
Start
Mar 2014
Primary completionActual
Jul 2014
CompletionActual
Jul 2014
Last update
Jul 22, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02084199
Lead sponsor
Galapagos NV
Responsible party
Sponsor
First posted
Mar 11, 2014
Start date
Mar 2014
Primary completion
Jul 2014
Completion
Jul 2014
Last update
Jul 22, 2014

Study contacts

Pille Harrison, MD
study director · Galapagos NV

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG0634

Start the discussion